Results 161 to 170 of about 19,188,680 (306)

Cost-effectiveness analysis of eltrombopag, hetrombopag and romiplostim for second-line treatment of primary immune thrombocytopenia in China. [PDF]

Front Med (Lausanne)
Chen X, Liu Y, Zhang J, Xu R, Guo C.
europepmc   +1 more source

Nivolumab—an effective second-line treatment for NSCLC [PDF]

Nature Reviews Clinical Oncology, 2015
openaire   +2 more sources

Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas

Molecular Oncology, EarlyView.
Cisplatin‐resistant cancer cells survive DNA‐damaging platinum‐based treatment yet remain sensitive to CuET‐induced proteotoxic stress. The distinct mechanism of action allows CuET to overcome and eliminate cisplatin‐resistant tumour cells, unless highly expressed metallothioneins (MTs) interfere with CuET, thereby highlighting MT levels as candidate ...
Stefanos Arampatzis, Tereza Buchtová, Jirina Bartkova, Marie Lund Bay, Christoffer Lynge Halvorsen, Zuzana Machacova, Zdenek Skrott, Martin Mistrik, Ekaterina Dulina, Miguel Andujar‐Sanchez, Estrid Høgdall, Tine Henrichsen Schnack, Claus Høgdall, Berit Jul Mosgaard, Marie Boennelycke, Jacob Brink Laursen, Allan Jensen, Susanne K. Kjær, Tuula Kallunki, Robert Strauss, Jiri Bartek   +20 more
wiley   +1 more source

An outer membrane vesicle‐associated two‐track model for enterotoxigenic Bacteroides fragilis oncogenesis

Molecular Oncology, EarlyView.
Enterotoxigenic Bacteroides fragilis is a gut bacterium linked to bowel cancer. We propose that its toxin acts along two routes: at the cell surface, cutting the adhesion protein E‐cadherin and triggering inflammation; and inside the cell, delivered by bacterial vesicles, switching on NOD1 and cancer stem cell programs.
Kangchan Choi, Sang‐Hyeon Yoo, Ki‐Jong Rhee   +2 more
wiley   +1 more source

Comparative Evaluation of the Effectiveness of Nivolumab Versus Axitinib in the Second-Line Treatment of Patients with Metastatic Renal Cell Carcinoma: A Two-Center Experience. [PDF]

J Clin Med
Buğday İ, Onur İD, İnanç M, Özkan M, Bozkurt O.   +4 more
europepmc   +1 more source

Raman‐based label‐free microscopic analysis of the pancreas in living zebrafish larvae

FEBS Open Bio, EarlyView.
Forward stimulated Raman scattering (F‐SRS) and epi coherent anti‐Stokes Raman scattering (E‐CARS) allow label‐free discrimination of distinct subcellular structures in the pancreas of living zebrafish larvae. Given the straightforward applicability, we anticipate broad implementation of Raman microscopy in other organs and across various biomedical ...
Noura Faraj, Eline M. F. de Lange, Klaas A. Sjollema, Ben N. G. Giepmans   +3 more
wiley   +1 more source

Pembrolizumab: A reliable second‐line treatment option for advanced esophageal cancer

Thoracic Cancer, 2022
Li Zheng, Yabi Zhu, Yangyang Liu, Xu Ma, Fang Xu   +4 more
doaj   +1 more source

Navigating first- and second-line treatment options in hormone receptor-positive HER2-negative advanced breast cancer. [PDF]

Oncologist
Sandoval J, Neven P, Emde A, Bidard FC, Aftimos P, Llombart A, Ciruelos E, Fasching PA, Li H, Campone M, Coersmeyer M, Srock S, Gnant M, Barrios C.   +13 more
europepmc   +1 more source

Single‐molecule DNA flow‐stretch assays for high‐throughput DNA–protein interaction studies

FEBS Open Bio, EarlyView.
We describe an optimised single‐molecule DNA flow‐stretch assay that visualises DNA–protein interactions in real time. Linear DNA fragments are tethered to a surface and stretched by buffer flow for fluorescence imaging. Using λ and φX174 DNA, this protocol enhances reproducibility and accessibility, providing a versatile approach for studying diverse ...
Ayush Kumar Ganguli, Mohammad Nour Alsamsam, Ugnė Bagdonaitė, Van Truc Vu, Chun‐Jen Huang, Polina Kuzhir, Mindaugas Zaremba, Aurimas Kopūstas, Marijonas Tutkus   +8 more
wiley   +1 more source

Case Report: Remarkable response to savolitinib plus chemotherapy and bevacizumab in second-line treatment of MET amplified colon cancer with liver metastasis. [PDF]

Front Oncol
Huang Y, Shu P, Gu S, Wen F, Wang X.
europepmc   +1 more source